Loading
CRISPR and Genetic Engineering / Cancer Related Gene Regulation · Journal article
Nature Communications · August 26, 2026
Raises a question worth testing. It does not answer one.
This work identifies Methylation Mesa as structurally conserved, narrow epigenetic regulatory elements that show superior correlation with gene activation compared to canonical promoters, and demonstrates via targeted CRISPR-based demethylation that Mesa are causal drivers of transcriptional activation and in vivo tumor suppression in murine models. The finding is mechanistic and exploratory, establishing a conceptual framework and proof-of-principle tool (CRISPR-DiR) but lacking independent replication or clinical validation.
Integrated bisulfite sequencing, functional CRISPR validation, and murine in vivo model study. Diverse human and murine cell and tissue models; in vivo studies used murine tumor models.. Intervention: CRISPR-DiR targeted demethylation of Methylation Mesa and proximal promoter regions, particularly the CDKN2A Mesa seed.. Compared with: Proximal promoter demethylation; CRISPR-TET1 (qualitative comparison on spatial precision, potency, and toxicity, not quantified)..
Methylation Mesa are structurally conserved epigenetic elements of ~45–300 bp width enriched in 5' untranslated regions Mesa show significantly better correlation with transcriptional activation than canonical promoter CpG islands Focal CRISPR-DiR demethylation of the CDKN2A Mesa seed drove exponential p16 reactivation and robust in vivo tumor suppression
CRISPR-DiR showed greater spatial precision, higher potency, and reduced toxicity compared to CRISPR-TET1
This is exploratory mechanistic work identifying a potential new class of epigenetic regulatory elements. While the CRISPR-DiR tool and Mesa concept may inform future targeted epigenetic therapies, the findings require independent replication and translation to human clinical settings before clinical application.
This is a mechanistic discovery study identifying a novel epigenetic element class (Methylation Mesa) and demonstrating proof-of-concept that targeted demethylation drives gene activation in cell models, but lacks clinical endpoint data or confirmatory independent validation.
As stated by the source record.
Quoted from the source exactly as published.
This is exploratory mechanistic work identifying a potential new class of epigenetic regulatory elements. While the CRISPR-DiR tool and Mesa concept may inform future targeted epigenetic therapies, the findings require independent replication and translation to human clinical settings before clinical application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
DNA methylation regulates transcription, yet the demethylation of canonical elements like promoter CpG islands exhibits inconsistent correlations with gene activation. We hypothesize that causal regulatory elements are defined by biophysical hypersensitivity. Profiling 24 whole-genome bisulfite sequencing samples across diverse human and murine models, we identify Methylation Mesa, narrow (~45-300 bp), structurally conserved epigenetic regulatory elements. Mesa show enrichment in 5’ untranslated regions and associate with transcriptional activation significantly better than canonical promoters. To investigate causal regulatory dynamics, we develop CRISPR-DiR, an RNA-based targeted demethylation technology offering greater spatial precision, higher potency, and reduced toxicity compared to CRISPR-TET1. While proximal promoter demethylation initiated limited early transcription, focal demethylation of the Mesa seed acts as the primary driver of exponential CDKN2A (p16) reactivation and robust in vivo tumor suppression. We demonstrate that precise demethylation of a Mesa locus triggers localized demethylation, subsequent activation histone mark deposition, and long-range three-dimensional chromatin rewiring. Thus, Methylation Mesa act as precise, dominant epigenetic regulatory hubs, and CRISPR-DiR as a potent high-resolution tool, establishing a structural framework for biomarker discovery and targeted therapies. DNA methylation influences gene expression, but the regulatory importance of specific methylated regions is unclear. Here, the authors identify “Methylation Mesa” as focal epigenetic regulatory elements and show that precise Mesa demethylation drives gene activation, chromatin remodeling and tumor suppression.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.